Barbara K. Finck, M.D., Appointed to ReForm Biologics Board of Directors

-- Brings 25 years of preclinical and clinical drug development experience to ReForm --

WOBURN, Mass.--(BUSINESS WIRE)--ReForm Biologics, a company developing a new generation of bio-innovative biologic medicines to improve patient access, safety and convenience, today announced the appointment of Barbara Finck, M.D., to its Board of Directors. Dr. Finck is currently the acting Chief Medical Officer at Coherus BioSciences.

“Dr. Finck’s experience in the successful clinical development of groundbreaking therapies such as Ditropan-XL^® and Enbrel^® will be invaluable to ReForm Biologics as we pivot to the in-house development of our own bio-innovative medicines,” said Jim Sherblom, Chairman of the Board. “Barbara’s unwavering commitment to the development of therapies that improve and extend human lives will help guide the development of biologics that can be more easily and safely administered to patients living with debilitating illnesses. We look forward to working with Barbara as we build our clinical capabilities at ReForm.”

“Biologics have changed the way we treat disease but they generally require in-clinic intravenous infusions that are inconvenient and often difficult to administer to fragile patients, particularly children who have smaller veins,” said Dr. Finck. “ReForm’s ability to reformulate biologics provides the opportunity to deliver these proven therapies in the clinic or at home through subcutaneous injections that could be safe, more convenient and encourage better compliance. I look forward to working with the ReForm team to improve patient care by making biologics more accessible for patients.”

Dr. Finck is a board certified rheumatologist with more than 25 years of preclinical and clinical drug development experience in academic and biopharmaceutical settings. Dr. Finck, whose drug development activities have spanned multiple therapeutic areas, started her pharmaceutical career at ALZA as medical director for early clinical development of Ditropan-XL^®, to treat spasms of the bladder. She subsequently held senior level positions at a half-dozen innovative biopharmaceutical companies. At Immunex (later acquired by Amgen), she was lead medical director for the Phase III clinical development of Enbrel^® in rheumatoid arthritis and juvenile idiopathic arthritis. At Eos Biotechology, she was VP of Clinical Development. In addition, she was on the executive teams at PDL Biopharma (VP, Clinical Development), Osprey Pharmaceuticals USA, Inc. (Senior VP, Research and Development, and Chief Medical Officer), and NKT Therapeutics, Inc. (Chief Medical Officer). In her role as the Chief Medical Officer at Coherus, she was instrumental in the development and approval of UDENYCA^®, a biosimilar pegfilgrastim.

About ReForm Biologics

ReForm Biologics creates gentler therapies for fragile patients, including pediatric patients, by using our proprietary technology to transform intravenous drugs into subcutaneous injections, to reduce adverse reactions, and to improve drug stability. Our goal is to enhance comfort, convenience, safety and compliance so that patients living with debilitating diseases can experience a better life while treating their medical conditions. For more information, visit www.reformbiologics.com.